Stock Price
TSX:MDS
PRICE: $
CHANGE:
VOLUME:386,822
NYSE:MDZ
PRICE: $
CHANGE:
VOLUME:55,075
Investor Information
122.0 million shares outstanding
(April 30, 2008)
Market cap of C$ 2.43 billion
(April 30, 2008)
Investor Links
Corporate Profile
MDS (TSX: MDS; NYSE: MDZ) is a global life sciences company with US$1.1 billion in net revenues that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of analytical instruments, medical isotopes for molecular imaging, radiotherapeutics and sterilization technologies and pharmaceutical contract research. MDS products and services reach people in more than 62 countries around the world with 95% of revenues from global markets.
MDS continues to make changes to strengthen the company's position as a leading innovator in global life sciences markets. The company is executing a growth strategy that focuses exclusively on opportunities within the fast growing life sciences markets served by the Company's three core businesses:
- MDS Analytical Technologies is a leading innovator in providing products, services and new tools that support drug discovery and development and analytical measurement . It operates in an estimated US$6 billion market with 6% - 10% growth rates.
- MDS Nordion is a world leader in providing innovative technologies for use in medical imaging, targeted cancer treatments and sterilization of medical products. It operates in an estimated US$4 billion market that is growing 5% - 7% a year.
- MDS Pharma Services is a leading contract research organization that provides both early stage and late stage drug discovery and development services to pharmaceutical and biotech companies through 39 sites in 29 countries around the world. It operates in an estimated US$15 billion market that is growing 10% - 13% annually.
MDS was founded in 1969 and now has more than 5,500 highly skilled people operating in 29 countries.
MDS trades on the Toronto Stock Exchange (TSX: MDS) and on the New York Stock Exchange (NYSE: MDZ). MDS is part of the S&P/TSX 60 and the S&P/TSX Capped Health Care Index
Financial Summary
 |
|
|
|
| (USD$ millions except EPS & LTD ratio) | 2007 | 2006 | 2005 |
| Net Revenues | 1,119 | 955 | 887 |
| Net income | 773 | 120 | (7) |
| Cash from continuing operations | 178 | 25 | 48 |
| Shareholders’ equity | 1,897 | 1,354 | 1,157 |
| Earnings per share - diluted | 5.86 | 0.83 | (0.05) |
| Earnings per share – continuing operations | (0.25) | 0.15 | (0.21) |
| Long-term debt to equity ratio | 20% | 29% | 34% |
Investment Thesis
- MDS is a US$1.1B global life sciences company with three strong leading platforms in attractive markets.
- Strong management with a proven track record of execution.
- Customer-focused and performance-driven culture; provider of innovative, high-quality products and services.
- Appropriate balance of operating improvement, growth and investment.
Analyst Coverage
MDS Inc. is followed by the analysts listed below.
| Company | Analyst | Telephone |
| CIBC World Markets | Maxime Paris | 514.847.6620 |
| Desjardins Securities | Maher Yaghi | 514.281.8664 |
| Dundee Securities | Dave Martin | 416.350.3477 |
| Goldman Sachs | Randall Stanicky | 212 357 3292 |
| Jefferies & Company | David Windley | 615.963.8313 |
| Raymond James | Brian Bapty | 604.659.8238 |
| RBC Dominion Securities | Doug Miehm | 416.842.7823 |
| Scotia Capital | John Maletic | 416.863.7708 |
| TD Newcrest | Lennox Gibbs | 416.308.2213 |
Auditors
Ernst & Young LLP
Transfer Agent
CIBC Mellon Trust Company
Toronto, Ontario, Canada
Telephone: 1-800-387-0825
Answer Line: 416-643-5500
Email: inquiries@cibcmellon.com
Investor Relations Contact Information
Kim Lee
Senior Director, Investor Relations
MDS Inc.
416.213.4721
kim.lee@mdsinc.com
2700 Matheson Blvd. East
Suite 300, West Tower
Mississauga, Ontario
L4W 4V9
Canada